• KRAS G12C inhibitor sotorasib plus panitumumab prolongs PFS in phase III trial

    The CodeBreaK 300 trial demonstrated that sotorasib combined with panitumumab overcame EGFR feedback reactivation and significantly prolonged progression-free survival in KRAS G12C-mutant CRC, a rare subtype found in 2-3% of cases. (Gan To Kagaku Ryoho)